Molecular Characterization of Novel Germline Deletions Affecting SDHD and SDHC in Pheochromocytoma and Paraganglioma Patients

Endocrine-Related Cancer - United Kingdom
doi 10.1677/erc-09-0084
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Tumour Risks and Genotype–phenotype–proteotype Analysis of Patients With Germline Mutations in the Succinate Dehydrogenase Subunit Genes SDHB, SDHC, and SDHD

The Lancet
Medicine
2016English

Role of MDH2 Pathogenic Variant in Pheochromocytoma and Paraganglioma Patients

Genetics in Medicine
MedicineGenetics
2018English

Metabolic Implications of Hypoxia and Pseudohypoxia in Pheochromocytoma and Paraganglioma

Cell and Tissue Research
Forensic MedicinePathologyHistologyCell Biology
2018English

Clinical Characteristics of Transient Cardiomyopathy in Patients With Surgically Resected Pheochromocytoma and Paraganglioma

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

FGF21 Levels in Pheochromocytoma/Functional Paraganglioma

Cancers
Cancer ResearchOncology
2019English

Efficacy and Safety of Ablative Therapy in the Treatment of Patients With Metastatic Pheochromocytoma and Paraganglioma

Cancers
Cancer ResearchOncology
2019English

Metabolic Impact of Pheochromocytoma/Paraganglioma: Targeted Metabolomics in Patients Before and After Tumor Removal

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2019English

Precision Medicine in Pheochromocytoma and Paraganglioma: Current and Future Concepts

Journal of Internal Medicine
Internal Medicine
2016English

Therapies Targeting the Signal Pathways of Pheochromocytoma and Paraganglioma

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy